A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

Summary

The purpose of the clinical study is to assess safety, tolerability and pharmacokinetics of RMC-035 for the prevention and treatment of acute kidney injury (AKI) in patients undergoing cardiac surgery.

Timeline

Start

2021-03-16

Primary completion

2021-07-15

Completion

2021-07-15

Outcome

Met primary endpoint

release “Fas 1b-studien uppfyllde sitt primära mål och har legat till grund för bolagets pågående kliniska fas 2-studie AKITA.” guardtherapeutics.com ↗

Drugs

Indications